What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer? (Q27012886)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article

Language	Label	Description	Also known as
English	What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?	scientific article

Statements

scholarly article

1 reference

What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer? (English)

0 references

0 references

immuno-oncology

1 reference

based on heuristic

inferred from title

author name string

M. Reck

1

1 reference

language of work or name

1 reference

publication date

September 2012

1 reference

Annals of Oncology

1 reference

23 Suppl 8

1 reference

viii28-34

1 reference

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS260

21 January 2018

Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS260

21 January 2018

The noninvasive staging of non-small cell lung cancer: the guidelines

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS260

21 January 2018

Role of genotyping in non-small cell lung cancer treatment: current status

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS260

21 January 2018

Second-line Treatment for Non–Small-Cell Lung Cancer: One Size Does Not Fit All

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS260

21 January 2018

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS260

21 January 2018

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS260

21 January 2018

Target therapies in lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS260

21 January 2018

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS260

21 January 2018

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS260

21 January 2018

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS260

21 January 2018

Long-Term Survival for Patients With Non–Small-Cell Lung Cancer With Intratumoral Lymphoid Structures

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS260

21 January 2018

Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS260

21 January 2018

Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS260

21 January 2018

A high number of CD8+ T cells infiltrated in NSCLC tissues is associated with a favorable prognosis.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS260

21 January 2018

The anticancer immune response: indispensable for therapeutic success?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS260

21 January 2018

Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS260

21 January 2018

Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS260

21 January 2018

Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS260

21 January 2018

Intratumoral neoadjuvant immunotherapy using IL-12 and dendritic cells is an effective strategy to control recurrence of murine hepatocellular carcinoma in immunosuppressed mice

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS260

21 January 2018

L-BLP25: a peptide vaccine strategy in non small cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS260

21 January 2018

Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS260

21 January 2018

Lactoferrin accelerates reconstitution of the humoral and cellular immune response during chemotherapy-induced immunosuppression and bone marrow transplant in mice.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS260

21 January 2018

Recombinant human lactoferrin prevents NSAID-induced intestinal bleeding in rodents

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS260

21 January 2018

Recombinant human lactoferrin ingestion attenuates indomethacin-induced enteropathy in vivo in healthy volunteers

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS260

21 January 2018

PD-1 and its ligands in tolerance and immunity

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS260

21 January 2018

Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS260

21 January 2018

Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS260

21 January 2018

Role of PD-1 in Regulating T-Cell Immunity

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS260

21 January 2018

Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS260

21 January 2018

Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer—Preclinical Background: CTLA-4 and PD-1 Blockade

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS260

21 January 2018

Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS260

21 January 2018

Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS260

21 January 2018

Identifiers

10.1093/ANNONC/MDS260

0 references

release_bvfmpljrujetzewlxn47ksocg4

1 reference

https://api.fatcat.wiki/v0/release/bvfmpljrujetzewlxn47ksocg4

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27012886&oldid=1843418146"